New medicine to treat infections in adults
Vabomere, a combination of an antibiotic and new beta-lactamase inhibitor, addresses bacterial resistance
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Vabomere (meropenem trihydrate/vaborbactam), a new treatment option against the following infections in adults:
- Complicated urinary tract infection, including pyelonephritis, a sudden and severe infection causing the kidneys to swell and which may permanently damage them;
- Complicated intra-abdominal infection;
- Hospital-acquired pneumonia, including ventilator associated pneumonia;
- Bacteria in the blood associated with any of the infections listed above;
- Infections due to aerobic Gram-negative organisms in adults with limited treatment options.
The lack of availability of medicines to treat patients with infections caused by resistant bacteria has become a major problem in recent years. It is estimated that at least 25,000 patients in the European Union (EU) die each year from infections due to bacteria that are resistant to many medicines.
Vabomere is a fixed combination of vaborbactam, a new beta-lactamase inhibitor and meropenem, a broad-spectrum antibiotic belonging to the class of carbapenems that is already approved for use in the EU. It is a powder for concentrate for solution for infusion (drip into a vein).
Resistance to carbapenems has been increasing lately, in particular in Gram-negative bacteria, and is of major concern. Beta-lactamases are enzymes involved in bacterial resistance to these antibiotics. By inhibiting the action of beta-lactamases, vaborbactam protects meropenem from being inactivated and restores its activity against many, but not all, carbapenem-resistant pathogens.
In the clinical development program, the exposure to vaborbactam at the recommended dose was shown to be sufficient to protect the activity of meropenem against carbapenem-resistant Enterobacteriaceae. The CHMP also agreed that the studies did not indicate any major concerns regarding the safety profile of meropenem-vaborbactam.
EMA contributes to the European and global effort to tackle antimicrobial resistance. A major area of activity is to create an environment that stimulates and facilitates the development of new antimicrobials. The Agency’s activities also include the monitoring and analysis of data on antimicrobials to guide policy and research, as well as the promotion of their responsible use.
The opinion adopted by the CHMP is an intermediary step on Vabomere’s path to patient access. The opinion will now be sent to the European Commission for the adoption of a decision on an EU-wide marketing authorisation. Once the marketing authorisations has been granted, decisions about price and reimbursement will take place at the level of each Member State, taking into account the potential role/use of this medicine in the context of the national health system of that country.
- The applicant for is Rempex London Ltd.
|New medicine to treat infections in adults||(English only)||21/09/2018|
Latest News from
EU-OSHA looks forward to a successful European Week for Safety and Health at Work 201822/10/2018 15:25:00
This year’s theme, at the heart of an exciting range of activities from 22 to 26 October, is managing dangerous substances in the workplace.
Hormone-free beef: Council authorises launch of negotiations with the United States22/10/2018 13:25:00
On 19 October, the Council authorised the EC to open negotiations on an agreement with the United States on imports of high quality beef from animals not treated with certain growth promoting hormones.
Mergers: EC approves acquisition of GitHub by Microsoft22/10/2018 11:25:00
The EC has approved under the EU Merger Regulation the proposed acquisition of GitHub by Microsoft. The Commission concluded that effective competition in the relevant markets would continue and Microsoft would have no incentive to undermine the open nature of GitHub's platform.
ESMA data analysis values EU derivatives market at €660 trillion with central clearing increasing significantly19/10/2018 15:10:00
The European Securities and Markets Authority (ESMA) has published its first Annual Statistical Report on the European Union’s (EU) derivatives markets.
Digital single market: a directory of European films to facilitate on-line access19/10/2018 14:10:00
Mariya Gabriel, the Commissioner for Digital Economy & Society, has presented the prototype of a directory of European films, a key action of the Digital4Culture strategy which is also part of the European Year of Cultural Heritage 2018.
Improving economic governance in the EU19/10/2018 13:10:00
At its October plenary session, the EESC adopted a package of three opinions on EU economic governance, providing European decision-makers with new input for the ongoing discussions on deepening Economic and Monetary Union (EMU) and the next European Semester exercise.
European Council meetings on 17 and 18 October 201819/10/2018 12:10:00
Remarks by President Donald Tusk after the European Council meetings
Relocation of European Medicines Agency & European Banking Authority18/10/2018 15:25:00
Today the Permanent Representatives Committee (Coreper) approved, on behalf of the Council, an agreement with the European Parliament on the text of the regulations for the relocation of the European Medicines Agency (EMA) to Amsterdam, and of the European Banking Authority (EBA) to Paris.
DiscoverEU: 12,000 additional free tickets available for 18-year-olds to discover Europe18/10/2018 13:25:00
Following the success of the first round of DiscoverEU, the European Commission will launch a second competition for free tickets on 29 November 2018.
EASO publishes a Country of Origin Information (COI) report on the security situation in Pakistan17/10/2018 14:25:00
The European Asylum Support Office has published a Country of Origin Information Report entitled ‘Pakistan security situation’. TThe report provides information relevant for the protection status determination of Pakistani asylum seekers.